Applied Therapeutics, Inc. (NASDAQ:APLT) Stock Position Increased by Marshall Wace LLP

Marshall Wace LLP increased its stake in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 144.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,307,381 shares of the company's stock after buying an additional 773,377 shares during the period. Marshall Wace LLP owned about 1.12% of Applied Therapeutics worth $1,124,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of Applied Therapeutics by 186.1% in the 3rd quarter. Barclays PLC now owns 200,012 shares of the company's stock worth $1,702,000 after purchasing an additional 130,102 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Applied Therapeutics by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company's stock valued at $268,000 after buying an additional 47,983 shares during the last quarter. SG Americas Securities LLC raised its stake in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock valued at $35,000 after buying an additional 25,601 shares in the last quarter. Private Advisor Group LLC bought a new position in Applied Therapeutics during the 4th quarter worth approximately $35,000. Finally, Swiss National Bank acquired a new position in shares of Applied Therapeutics in the 4th quarter worth approximately $126,000. 98.31% of the stock is owned by institutional investors and hedge funds.

Applied Therapeutics Trading Down 1.0 %

Applied Therapeutics stock traded down $0.00 during mid-day trading on Monday, reaching $0.46. The company's stock had a trading volume of 415,754 shares, compared to its average volume of 3,198,438. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62. The business has a 50 day moving average price of $0.44 and a 200-day moving average price of $2.45. The firm has a market cap of $64.56 million, a price-to-earnings ratio of -0.28 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last issued its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to analysts' expectations of $0.61 million. On average, equities analysts expect that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.